AI assistant
Q32 Bio Inc. — Director's Dealing 2018
Mar 29, 2018
34891_dirs_2018-03-28_2a65effd-5811-4551-af35-02dd5f1bdaea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-28
Reporting Person: TLS Beta Pte. Ltd. (10% Owner)
Reporting Person: Temasek Life Sciences Private Ltd (10% Owner)
Reporting Person: Fullerton Management Pte Ltd (10% Owner)
Reporting Person: Temasek Holdings (Private) Ltd (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $ | Common Stock (1605681) | Indirect | ||
| Series B Preferred Stock | $ | Common Stock (989612) | Indirect |
Footnotes
F1: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F2: The securities reported herein are held of record by TLS Beta Pte. Ltd, which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.